195 related articles for article (PubMed ID: 28529321)
21. Oral chemotherapy for colorectal cancer: some economic considerations.
Saltz L
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):29-32. PubMed ID: 11219974
[TBL] [Abstract][Full Text] [Related]
22. The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash.
Saltz LB
JAMA Oncol; 2015 May; 1(2):141-2. PubMed ID: 26181010
[No Abstract] [Full Text] [Related]
23. Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.
Kelly RJ; Forde PM; Elnahal SM; Forastiere AA; Rosner GL; Smith TJ
J Oncol Pract; 2015 Jul; 11(4):308-12. PubMed ID: 26015459
[TBL] [Abstract][Full Text] [Related]
24. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
Dranitsaris G; Ortega A; Lubbe MS; Truter I
J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab.
Graham J; Muhsin M; Kirkpatrick P
Nat Rev Drug Discov; 2004 Jul; 3(7):549-50. PubMed ID: 15272498
[No Abstract] [Full Text] [Related]
26. [Expensive cancer drugs funding is undergoing turbulent times].
Bay JO; L'Allemain G; Vignot S
Bull Cancer; 2016 Apr; 103(4):313-4. PubMed ID: 27102881
[No Abstract] [Full Text] [Related]
27. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
28. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
29. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
30. Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Viale PH; Fung A; Zitella L
Clin J Oncol Nurs; 2005 Oct; 9(5):541-52. PubMed ID: 16235581
[TBL] [Abstract][Full Text] [Related]
31. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
32. Putting a cost on extra days given by drugs.
Singer JW
Pharos Alpha Omega Alpha Honor Med Soc; 2008; 71(2):44; author reply 44. PubMed ID: 18686539
[No Abstract] [Full Text] [Related]
33. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
Rautenberg T; Siebert U; Arnold D; Bennouna J; Kubicka S; Walzer S; Ngoh C
J Med Econ; 2014 Feb; 17(2):99-110. PubMed ID: 24215550
[TBL] [Abstract][Full Text] [Related]
34. Making a case for a $2700-a-month drug.
Sibbald B
CMAJ; 1999 Nov; 161(9):1173. PubMed ID: 10569111
[No Abstract] [Full Text] [Related]
35. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
Annemans L; Van Cutsem E; Humblet Y; Van Laethem JL; Bleiberg H
Acta Clin Belg; 2007; 62(6):419-25. PubMed ID: 18351186
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis in Colorectal Cancer: Antibodies.
Chan E
Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
[TBL] [Abstract][Full Text] [Related]
37. Reader comments on the cost of cancer care.
Toftbagen C
Clin J Oncol Nurs; 2006 Feb; 10(1):15; author reply 15-6. PubMed ID: 16482722
[No Abstract] [Full Text] [Related]
38. [Targeted cancer drugs and their development].
Kaje-Reinikainen S
Duodecim; 2005; 121(2):189; author reply 189. PubMed ID: 15745358
[No Abstract] [Full Text] [Related]
39. [Patients with cancer denied treatment with new expensive drugs].
Linné T
Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1298. PubMed ID: 22852261
[No Abstract] [Full Text] [Related]
40. Era of personalized medicine may herald end of soaring cancer costs.
Keogh B
J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
